Última actualización 12 de septiembre de 2026
Key finding
cDI increased by 0.2 (63.2% change)
This study investigated the effects of chronic GIP receptor activation on insulin sensitivity in adults with type 2 diabetes, finding significant improvements in insulin metrics.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of chronic GIP receptor activation on insulin sensitivity in adults with type 2 diabetes, finding significant improvements in insulin metrics.
Improving insulin sensitivity is crucial for managing type 2 diabetes, as it can lead to better blood sugar control and reduced risk of complications. The findings from this study highlight the potential of GIP receptor activation as a therapeutic strategy, offering new avenues for treatment in diabetic patients.
Effectiveness of interventions remains unclear due to insufficient data Limited generalizability due to specific population characteristics Potential unmeasured confounders impacting results
Published in
Publication details and source links for this paper.
Tim H, Eric Z, Andrea M, et al. Chronic GIP receptor activation improves insulin sensitivity in adults with type 2 diabetes. Diabetes, Obesity & Metabolism. 2026;28(8):7196-7206. doi:10.1111/dom.70863
Clamp disposition index (cDI) increased by 0.2 (63.2% change)
Clamp disposition index (cDI) increased by 0.5 (181.0% change)
Insulin secretion rate (ISR) increased by 191.1 (163.6% change)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Combination of Macupatide and Dulaglutide, Dulaglutide, Macupatide and Disposition Index, Glucose variability parameters M value, Insulin secretion rate (ISR) during GGIT.
This study contributes evidence to
Primary intervention
Combination of Macupatide and Dulaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
9
Evidence pairs
100
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_intervention
Core evidence
The primary outcomes reported in this study.
Combination of Macupatide and Dulaglutide → Disposition Index
Combination of Macupatide and Dulaglutide → Disposition Index
Combination of Macupatide and Dulaglutide → Glucose variability parameters M value
Combination of Macupatide and Dulaglutide → Glucose variability parameters M value
Combination of Macupatide and Dulaglutide → Insulin secretion rate (ISR) during GGIT
Combination of Macupatide and Dulaglutide → Insulin secretion rate (ISR) during GGIT
Dulaglutide → Glucose variability parameters M value
Dulaglutide → Glucose variability parameters M value
Dulaglutide → Insulin secretion rate (ISR) during GGIT
Dulaglutide → Insulin secretion rate (ISR) during GGIT
Macupatide → Glucose variability parameters M value
Macupatide → Glucose variability parameters M value
Macupatide → Insulin secretion rate (ISR) during GGIT
Macupatide → Insulin secretion rate (ISR) during GGIT
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Combination of Macupatide and Dulaglutide and Disposition Index, Combination of Macupatide and Dulaglutide and Glucose variability parameters M value.
This study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Behavioral & Lifestyle
Curated evidence collections and hubs this study is part of.
All studies on Combination of Macupatide and Dulaglutide
Contributes to Combination of Macupatide and Dulaglutide evidence base.
All studies measuring Disposition Index
Measures Disposition Index as a key outcome.
All studies measuring Glucose variability parameters M value
Measures Glucose variability parameters M value as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Combination of Macupatide and Dulaglutide appears to improve disposition index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Disposition Index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Combination of Macupatide and Dulaglutide appears to improve glucose variability parameters m value.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose variability parameters M value
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Combination of Macupatide and Dulaglutide appears to improve insulin secretion rate (ISR) during ggit.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Insulin secretion rate (ISR) during GGIT
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dulaglutide appears to improve disposition index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Disposition Index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
